Concepedia

Ida Paris

IP

Statistics

Publications

5

Citations

277

H-Index

5

Active since

2022

Affiliations

Istituti di Ricovero e Cura a Carattere Scientifico(Current)

Agostino Gemelli University Polyclinic

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Fondazione IRCCS Istituto Nazionale dei Tumori

Ospedale Policlinico San Martino

Ida Paris is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in oncology, medicine, and breast oncology.

Publications per year

2022–2024

5

Publications

5

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

Aditya Bardia, Komal Jhaveri, Seock‐Ah Im et al. · Journal of Clinical Oncology · 2024 · 140 citations · Full text

, , +17

Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis

Roberta Caputo, Giuseppe Buono, Michela Piezzo et al. · Frontiers in Oncology · 2024 · 73 citations · Full text

, , +17

Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study

Andrea Botticelli, Roberta Caputo, Simone Scagnoli et al. · The Oncologist · 2023 · 36 citations · Full text

, , +17

Abstract GS3-07: Circulating tumor DNA (ctDNA) dynamics in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioItaLEE trial

Giampaolo Bianchini, Luca Malorni, Grazia Arpino et al. · Cancer Research · 2022 · 17 citations

, , +17

Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients

Elena Giordani, Matteo Allegretti, Alberto Sinibaldi et al. · Journal of Experimental & Clinical Cancer Research · 2024 · 11 citations · Full text

, , +17

1–5 of 5